Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOrthopedics/MusculoskeletalBlue Cross ND ACI Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North DakotaPolicy 87

    Autologous Chondrocyte Implantation for Focal Articular Cartilage Lesions

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - North Dakota Policy 87 alerts

    Get alerted when Policy 87 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of autologous chondrocyte implantation, including matrix-induced ACI, for disabling full-thickness articular cartilage defects of the knee when clinical, anatomic, age or skeletal maturity, biomechanical, and BMI criteria are satisfied. Other joints and indications are considered investigational.

    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyAutologous Chondrocyte Implantation for Focal Articular Cartilage Lesions
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Last ReviewSep 1, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit history and physical or chart notes, including BMI, symptoms, diagnoses, treatments, and the name of the FDA-approved therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥1.5 cm²Minimum qualifying lesion size

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    BMI <35
    Required body mass index
    Grade III or IVRequired lesion grade
    Knee onlyCovered anatomic site
    InvestigationalOther joints and indications

    Medical Necessity and Investigational Criteria

    Medically Necessary ACI for Qualifying Knee Defects

    ACI may be considered medically necessary when ALL of the following criteria are met:

    ALL of the following

    • The condition is a disabling, full-thickness articular cartilage defect of the knee caused by acute or repetitive trauma.
    • Age or skeletal maturity

      • The patient is an adolescent who is skeletally mature, with documented closure of the growth plates (e.g., age 15 years or older).
      • The patient is an adult who is too young to be considered an appropriate candidate for total knee arthroplasty or other reconstructive knee surgery (e.g., younger than 55 years).
    • The lesion is a focal, full-thickness (Outerbridge grade III or IV), unipolar lesion of the patella or the weight-bearing surface of the femoral condyles or trochlea.>= 1.5 cm²
    • The surrounding articular cartilage has documented Outerbridge grade II or less degenerative changes, with normal-appearing hyaline cartilage surrounding the border of the defect.
    • Normal knee mechanics, alignment, and stability are present before the procedure or are planned to be restored simultaneously with ACI.
    • The patient's body mass index (BMI) is less than 35.BMI < 35

    Investigational ACI

    ACI is considered investigational when ANY of the following applies:

    ANY of the following

    • The knee condition does not meet all of the medically necessary criteria above.
    • ACI is performed for a joint other than the knee, including the talar joint.
    • ACI is used for an indication other than a disabling, full-thickness knee articular cartilage defect caused by acute or repetitive trauma.

    Medically Necessary

    Current evidence indicates that ACI can improve symptoms in some patients with articular cartilage lesions of the knee. ACI may be considered medically necessary when the policy criteria are met.

    ACI is medically necessary when the qualifying knee defect and all applicable clinical, anatomic, age or skeletal maturity, biomechanical, BMI, and lesion criteria are satisfied.

    Investigational

    ACI is considered investigational under either of the following conditions:

    ANY of the following

    • ACI is used to treat articular cartilage lesions of the knee in a patient who does not meet the policy criteria.
    • ACI is used for a joint other than the knee, including the patella or talar joint.

    Procedures involving joints other than the knee, including the talar joint, are excluded from the medically necessary criteria.

    Indications other than disabling, full-thickness articular cartilage defects of the knee caused by acute or repetitive trauma are considered investigational.

    Second-generation matrix-induced ACI implants described in European studies are not approved in the United States and are therefore considered investigational.

    ACI for lesions of joints other than the knee, including the patella and talus, is considered investigational because evidence is insufficient to evaluate efficacy and impact on health outcomes.

    Codes and Key Thresholds

    CPTCPT
    27412Autologous chondrocyte implantation, knee.
    HCPCSHCPCS
    J7330Autologous cultured chondrocytes, implant
    S2112Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)
    Qualifying lesion size
    Minimum lesion sizeAt least 1.5 cm²
    Lesion depthFocal, full-thickness Grade III or IV
    Qualifying locationPatella or weight-bearing surface of the femoral condyles or trochlea
    Body mass index
    Required BMILess than 35
    Severe obesity thresholdBMI greater than 35 kg/m² may affect outcomes
    Reason for consideration

    Documentation and Review Requirements

    Documentation Required

    Clinical History and Treatment Documentation

    Submit the clinical documentation needed to determine whether policy criteria are met, including the patient’s history and physical or chart notes, BMI, symptoms, associated diagnoses, treatments, and the name of the FDA-approved therapy being requested.

    • History and physical or chart notes, including BMI
    • Documentation of symptoms, associated diagnoses, and treatments
    • Name of the FDA-approved therapy
    Documentation Required

    Skeletal Maturity Documentation

    For adolescent patients, submit documentation confirming skeletal maturity and closure of the growth plates.

    • Documented growth-plate closure is required; the policy provides age 15 or older as an example of skeletal maturity.

    Clinical Background

    Autologous chondrocyte implantation (ACI) is a cartilage-repair procedure in which chondrocytes are harvested from healthy cartilage, expanded in vitro, and then implanted to resurface an articular cartilage defect. The procedure is technically complex and generally involves an initial biopsy followed by a separate implantation procedure and rehabilitation.

    Procedure and Product Definitions

    Autologous chondrocyte implantation (ACI)
    Cell sourceChondrocytes are harvested from healthy tissue
    Cell preparationThe harvested cells are expanded in vitro
    Implantation purposeThe expanded cells are implanted to resurface articular cartilage defects
    MACI
    TechniqueNext-generation matrix-induced autologous chondrocyte implantation technique
    FDA statusThe only ACI therapy currently approved by the FDA
    Cell and matrix composition
    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyAutologous Chondrocyte Implantation for Focal Articular Cartilage Lesions
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Last ReviewSep 1, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit history and physical or chart notes, including BMI, symptoms, diagnoses, treatments, and the name of the FDA-approved therapy.
    SourceLink
    On This Page
    Medical Necessity and Investigational CriteriaCodes and Key ThresholdsDocumentation and Review RequirementsClinical BackgroundProcedure and Product Definitions
    Increased stress on weight-bearing surfaces of the joint may affect outcomes
    Adult age example
    Adult age exampleYounger than 55 years
    Adult candidacyToo young to be considered an appropriate candidate for total knee arthroplasty or other reconstructive knee surgery
    Adolescent maturitySkeletally mature with documented closure of growth plates; for example, age 15 years or older
    Smaller lesion consideration
    Smaller lesion thresholdSmaller than 4 cm²
    Prior treatment considerationApplies when debridement is the only prior surgical treatment
    Recommended considerationConsider marrow-stimulating techniques before ACI is performed
    Documentation Required

    Imaging Documentation

    Provide imaging that supports the qualifying patellar or other eligible knee cartilage lesion and the documented degenerative changes.

    • Imaging supporting the patella lesion
    • Imaging supporting the degenerative changes
    Documentation Required

    Knee Mechanics and Alignment Documentation

    Document that normal knee biomechanics, alignment, and stability are present, or that these conditions will be restored concurrently with the requested autologous chondrocyte implantation procedure.

    • Knee biomechanics and alignment
    • Knee stability
    • Evidence that any abnormal mechanics, alignment, or stability will be addressed concurrently with the request
    Denial Risk

    Nonqualifying Joint, Indication, or Criteria

    Autologous chondrocyte implantation is considered investigational when the qualifying knee criteria are not met, for joints other than the knee—including the talar joint—and for indications other than those listed in the policy.

    • Knee cases that do not satisfy all policy criteria
    • ACI for other joints, including the talar joint
    • Indications outside the listed policy criteria
    Denial Risk

    Insufficient Clinical Documentation

    Submit complete documentation supporting medical necessity and each applicable policy criterion. If required information is missing, it could affect the review and the coverage decision outcome.

    • Missing clinical documentation may prevent confirmation that policy criteria are met.
    • Include all required history, examination, treatment, product, growth-plate, imaging, and knee mechanics documentation.
    Denial Risk

    Use of Non-U.S.-Approved Products

    Second-generation matrix-induced autologous chondrocyte implantation products reported in European studies that are not approved in the United States are considered investigational.

    • Verify that the requested product is approved for use in the United States.
    • European second-generation matrix-induced ACI products not approved in the United States are investigational.
    Denial Risk

    Knee Cases That Do Not Meet Criteria

    ACI for articular cartilage lesions of the knee is considered investigational when the patient does not meet the policy’s medical-necessity criteria.

    • This includes cases that fail any applicable criterion for the qualifying knee defect, surrounding cartilage, patient suitability, knee mechanics or alignment, or BMI.
    Denial Risk

    Non-Knee Joint Treatment

    ACI for joints other than the knee is considered investigational, including treatment of lesions involving the patella and talar joint as identified in the policy.

    • ACI for the patella is investigational under the policy’s other-joint limitation.
    • ACI for the talar joint is investigational.
    • Evidence is insufficient to evaluate ACI efficacy for joints other than the knee.
    Autologous chondrocytes cultured onto a bioresorbable porcine-derived collagen membrane
    Matrix-induced autologous chondrocyte implantation (MACI)
    Matrix compositionA matrix seeded with cultured autologous chondrocytes
    Difference from first-generation ACIUnlike first-generation periosteum-covered ACI, it does not require tibial or fibular osteotomy for adequate surgical access
    Procedure typeMatrix-induced autologous chondrocyte implantation